{'en': 'Novalab presents his novelties in diabetes', 'es': 'Novalab presenta sus novedades en diabetes'} Image

Novalab presents his novelties in diabetes

  
fer
04/19/2018 6:58 p.m.

Novalab will present its latest products linked to continuous glucose (MCG) monitoring on Thursday.It will do so in a mini symposium, under the title ‘The MCG in the technological ecosystem of diabetes’, which will take place this Thursday, April 19 during the XXIX thirst congress.

The company will have a stand with its latest news in technology applied to diabetes, especially with Cellnovo micro-pumps as protagonists.

In the Novalab stand will be the new Dexcom G5, the only approved MCG system for non -adjuvant use from 2 years of age.

As for the Mini Symposium, it will be moderated by Edelmiro Luís Menéndez Torro, of the Central University Hospital of Asturias, and will have Rosa Yelmo Valverde, nurse from the Universiatio Ramón y Cajal Hospital;and Eva Solá Izquierdo, doctor of the Dr. Peset University Hospital, as speakers.

Both will address the issue of continuous glucose monitoring from different perspectives, on the one hand, and the Valverde will do so with the ‘MCG presentation something more than a figure’;While Dr. Solá Izquierdo will do it with the talk ‘The MCG ahead and not because he is scared’.

In addition, the new Dexcom G5 will be at the Novalab stand, available for both Apple and Android devices and the only approved MCG system for non -adjuvant use and from 2 years of age.

Diabetes Tipo 1 desde 1.998 | FreeStyle Libre 3 | Ypsomed mylife YpsoPump + CamAPS FX | Sin complicaciones. Miembro del equipo de moderación del foro.

Autor de Vivir con Diabetes: El poder de la comunidad online, parte de los ingresos se destinan a financiar el foro de diabetes y mantener la comunidad online activa.

  
Regina
04/19/2018 9:12 p.m.

What will it mean that the Dexcom is the only approved MCG for non -adjuvant use?
It would be perfect if it was funded by the SS.

Hija de 35 años , diabética desde los 5. Glico: normalmente de 6 , pero 6,7 la última ( 6,2 marcaba el Free)
Fiasp: 4- 4- 3 Toujeo: 20

  
mamarvazq
04/21/2018 10:52 p.m.

Non -adjuvant use means that it can make therapeutic decisions only with its data without confirming with capillary glycems.

No signature configured, add it on your user's profile.
  
Regina
04/21/2018 11:13 p.m.

That seemed to me .., then, if it is the only one approved like this, it will be the one that has to be subsidized.

Hija de 35 años , diabética desde los 5. Glico: normalmente de 6 , pero 6,7 la última ( 6,2 marcaba el Free)
Fiasp: 4- 4- 3 Toujeo: 20

Join the Discussion!

To participate in this thread, please register or log in.

 

Support the Community: Buy "Living with Diabetes: The Power of the Online Community" 💙

Did you know that the forum operates without ads thanks to the book's revenue?
Each purchase helps us continue providing a space for support, learning, and connection for thousands of people with diabetes.

Why buy it?

You help keep this forum alive, a free and accessible community for everyone. You'll discover stories, advice, and experiences that transform the lives of those facing diabetes. With your support, we will continue sharing valuable information and resources for people with diabetes and their families.

💡 Every book counts. It's more than a purchase—it's an act of support that makes a difference.

👉 Buy the book now and be part of something great.

Thank you for being part of our community and for your constant support! 💙

 

See the book at